Developing pharmaceutical products is both time consuming and expensive. Intellectual property rights (IPRs) are considered an important means to encourage research and development in this area.
At the same time, there are increasing concerns, in particular in developing countries, about the effect IPRs may have on drug prices and availability.
This joint UNCTAD-Stockholm Network event will examine a number of controversial issues in the area of IPRs and public health, through an exchange of views from the industry and the public interest perspectives.
The debate is intended to inform stakeholders from Geneva-based Permanent Missions, intergovernmental organizations, civil society, industry and academia.